A 2:1 Randomised Phase II Study of NivolUmab and Temozolomide vs Temozolomide in Methylated newly diagnosed Elderly Glioblastoma (NUTMEG) [ 2017 - 2021 ]

Research Grant

Researchers: A/Pr Mustafa Khasraw (Principal investigator) ,  A/Pr Kerrie Mcdonald ,  A/Pr Matthew Foote ,  Dr Elizabeth Hovey ,  Dr Sonia Yip
View all 8 related researchers

Brief description Radiotherapy and Temozolomide (TMZ) chemotherapy treatment for the brain tumour glioblastoma (GBM) is not as effective in elderly patients. If their tumour has a genetic marker called "methylated MGMT", TMZ does work relatively better and is often given alone. Elderly GBM patients with this marker will be randomly selected in this trial to have TMZ alone or TMZ + Nivolumab - a drug that assists the immune system to attack cancer.

Funding Amount $AUD 1,648,862.92

Funding Scheme Project Grants

Notes Standard Project Grant